[1] PIANO S, TONON M, ANGELI P. Management of ascites and hepatorenal syndrome[J]. Hepatol Int, 2018, 12(Suppl 1): 122.
[2] NEONG SF, ADEBAYO D, WONG F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293. doi: 10.1080/17474124.2018.1555469
[3] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397. doi: 10.1016/j.jhep.2010.05.004
[4] RUNYON BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J]. Hepatology, 2013, 57(4): 1651. doi: 10.1002/hep.26359
[5] ZHUGE Y, LIU Y, XIE W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34(4): 634. doi: 10.1111/jgh.14612
[6] ZHUGE YZ, WANG Y, ZHANG F, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease[J]. Liver Int, 2018, 38(10): 1867. doi: 10.1111/liv.13684
[7] WANG Y, QIAO D, LI Y, et al. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study[J]. BMC Gastroenterol, 2018, 18(1): 156. doi: 10.1186/s12876-018-0879-7
[8] ANGELI P, BERNARDI M, VILLANUEVA C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406.
[9] MOORE KP, WONG F, GINES P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club[J]. Hepatology, 2003, 38(1): 258. doi: 10.1053/jhep.2003.50315
[10] ZHANG H, XIAO J, TU J, et al. Prevention of variceal rebleeding in cirrhotic patients with spontaneous portosystemic shunts: transjugular intrahepatic portosystemic shunt versus endoscopic treatment[J]. Eur J Gastroenterol Hepatol, 2021, 33(5): 752. doi: 10.1097/MEG.0000000000002079
[11] LENG XF, ZHANG F, ZHANG M, et al. Comparison of transjugular intrahepatic portosystemic shunt for treatment of variceal bleeding in patients with cirrhosis with or without spontaneous portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2019, 31(7): 853. doi: 10.1097/MEG.0000000000001349
[12] YIN X, ZHANG F, GUO H, et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in Cirrhotic Patients[J]. Sci Rep, 2020, 10: 9381. doi: 10.1038/s41598-020-65227-2
[13] ZHAO R, LU J, SHI Y, et al. Current management of refractory ascites in patients with cirrhosis[J]. J Int Med Res, 2018, 46(3): 1138. doi: 10.1177/0300060517735231
[14] ADEBAYO D, NEONG SF, WONG F. Refractory ascites in liver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1): 40. doi: 10.1038/s41395-018-0185-6
[15] NARAHARA Y, KANAZAWA H, FUKUDA T, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial[J]. J Gastroenterol, 2011, 46(1): 78. doi: 10.1007/s00535-010-0282-9
[16] BUREAU C, THABUT D, OBERTI F, et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites[J]. Gastroenterology, 2017, 152(1): 157. doi: 10.1053/j.gastro.2016.09.016
[17] DE FRANCHIS R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743. doi: 10.1016/j.jhep.2015.05.022
[18] GARCIA-TSAO, ABRALDES J G, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Associationfor the study of liver diseases[J]. Hepatology, 2017, 65(1): 310. doi: 10.1002/hep.28906
[19] 汪春燕, 尹梅. 以奥马哈系统为框架的健康行为干预在肝硬化病人家居防护中的应用[J]. 蚌埠医学院学报, 2019, 44(12): 1694.
[20] CHEN Y, XIONG F, WANG W, et al. The long persistence of pyrrolizidine alkaloid-derived pyrrole-protein adducts in vivo: Kinetic study following multiple exposures of a pyrrolizidine alkaloid containing extract of Gynura japonica[J]. Toxicol Lett, 2020, 323(1): 41.
[21] XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15(3): 720. doi: 10.1007/s12072-020-10126-x